Ferroptosis, a cell death process driven by iron-dependent phospholipid peroxidation, has
been implicated in various diseases. There are two major surveillance mechanisms to …

Pancreatic ductal adenocarcinoma (PDAC), a deadly cancer characterized by multiple
molecular alterations, remains the most lethal cancer, with a 5‐year survival rate of about 3 …

Expression levels of biomarkers are generally unknown at initial diagnosis. The
development of theranostic probes that do not rely on biomarker availability would expand …

Pancreatic ductal adenocarcinoma (PDAC), accounting for 90–95% of all pancreatic tumors,
is a highly devastating disease associated with poor prognosis. The lack of accurate …

Sonosensitizers in current sonodynamic therapy (SDT) often suffer from poor delivery
efficiency, phototoxicity, and disputed safety. To overcome these issues, a sonosensitizers …

Rationale: Following an ever-increased focus on personalized medicine, there is a
continuing need to develop preclinical molecular imaging modalities to guide the …

Patients with pancreatic ductal adenocarcinoma (PDAC) do not benefit from immune
checkpoint blockade (ICB) along the PD-1/PD-L1 axis. Variable PD-L1 expression in PDAC …

The incidence and lethality of pancreatic ductal adenocarcinoma (PDAC) will continue to
increase in the next decade. For most patients, chemotherapeutic combination therapies …

As many patients ultimately relapse after chimeric antigen receptor (CAR) T-cell therapy,
identification of alternative targets is currently being evaluated. Substantial research efforts …

Pancreatic cancer (PC) remains the fourth leading cause of cancer death; therefore, there is
a clinically unmet need for novel therapeutics and diagnostic markers to treat this …